Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 60 of the 60 references it cites were found in a registry or an index.

Genome and Transcriptome Sequencing in Prospective Metastatic Triple-Negative Breast Cancer Uncovers Therapeutic Vulnerabilities

Published version of a preprint

Abstract

Triple-negative breast cancer (TNBC) is characterized by the absence of expression of estrogen receptor, progesterone receptor, and HER-2. Thirty percent of patients recur after first-line treatment, and metastatic TNBC (mTNBC) has a poor prognosis with median survival of one year. Here, we present initial analyses of whole genome and transcriptome sequencing data from 14 prospective mTNBC. We have cataloged the collection of somatic genomic alterations in these advanced tumors, particularly those that may inform targeted therapies. Genes mutated in multiple tumors included TP53, LRP1B, HERC1, CDH5, RB1, and NF1. Notable genes involved in focal structural events were CTNNA1, PTEN, FBXW7, BRCA2, WT1, FGFR1, KRAS, HRAS, ARAF, BRAF, and PGCP. Homozygous deletion of CTNNA1 was detected in 2 of 6 African Americans. RNA sequencing revealed consistent overexpression of the FOXM1 gene when tumor gene expression was compared with nonmalignant breast samples. Using an outlier analysis of gene expression comparing one cancer with all the others, we detected expression patterns unique to each patient's tumor. Integrative DNA/RNA analysis provided evidence for deregulation of mutated genes, including the monoallelic expression of TP53 mutations. Finally, molecular alterations in several cancers supported targeted therapeutic intervention on clinical trials with known inhibitors, particularly for alterations in the RAS/RAF/MEK/ERK and PI3K/AKT/mTOR pathways. In conclusion, whole genome and transcriptome profiling of mTNBC have provided insights into somatic events occurring in this difficult to treat cancer. These genomic data have guided patients to investigational treatment trials and provide hypotheses for future trials in this irremediable cancer. Mol Cancer Ther; 12(1); 104–16. ©2012 AACR.

Overview

Integrity signals

Registry

Crossref · 10.1158/1535-7163.mct-12-0781

Cites

60 of 60 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Citations

Cites

Show all 60 references

Cited by

See all 222

Metadata

Authors
Craig, D. W., O'Shaughnessy, J. A., Kiefer, J. A., Aldrich, J., Sinari, S., Moses, T. M., Wong, S., Dinh, J., Christoforides, A., Blum, J. L., Aitelli, C. L., Osborne, C. R., Izatt, T., Kurdoglu, A., Baker, A., Koeman, J., Barbacioru, C., Sakarya, O., De La Vega, F. M., Siddiqui, A., Hoang, L., Billings, P. R., Salhia, B., Tolcher, A. W., Trent, J. M., Mousses, S., Von Hoff, D., & Carpten, J. D.
Affiliations
  • Translational Genomics Research Institute (US)
  • Authors' Affiliations: 1Translational Genomics Research Institute, Phoenix, Arizona; 2Baylor Sammons Cancer Center, Texas Oncology, US Oncology, Dallas; 3Texas Oncology, US Oncology, Fort Worth; 4South Texas Accelerated Research Therapeutics, START Center for Cancer Care, San Antonio, Texas; 5Van Andel Research Institute, Grand Rapids, Michigan; and 6Life Technologies, Carlsbad, California
Corresponding author
Carpten, John D.
Venue
Molecular Cancer Therapeutics
Published
2013-01-01
Volume
12
Issue
1
Pages
104-116
ISSN
  • 1535-7163 (ISSN-L)
  • 1538-8514
OpenAlex
W2134133462
Cited by
220
References
60
Citations by year
2026: 2 · 2025: 8 · 2024: 9 · 2023: 11 · 2022: 11 · 2021: 13 · 2020: 21 · 2019: 12 · 2018: 24 · 2017: 19 · 2016: 26 · 2015: 25 · 2014: 20 · 2013: 19
FWCI
6.77
Type
journal article
Language
en
Open access
closed
Locations
  • Molecular Cancer Therapeutics (publishedVersion)
  • PubMed (publishedVersion)
Funders
GlaxoSmithKline
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › BRCA gene mutations in cancer
Keywords
metastatic triple-negative breast cancer, somatic alterations, TP53 mutation, monoallelic expression, RAS/MAPK pathway, PI3K/AKT/mTOR pathway, targeted therapy, therapeutic vulnerabilities, African American patients, tumor heterogeneity
MeSH terms
Forkhead Box Protein M1, Adult, Breast Neoplasms, Chromosomes, Human, Pair 7, DNA Mutational Analysis, Female, Humans, Middle Aged, Neoplasm Metastasis, Prospective Studies, Receptors, Estrogen, Receptors, Progesterone, Signal Transduction, Gene Expression, Genome, Human, Tumor Suppressor Protein p53, Treatment Outcome, Sequence Deletion, Sequence Analysis, RNA, Erb-b2 Receptor Tyrosine Kinases, alpha Catenin, Forkhead Transcription Factors, Genes, Neoplasm, Genome-Wide Association Study, Molecular Targeted Therapy, High-Throughput Nucleotide Sequencing, Transcriptome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Genome and Transcriptome Sequencing in Prospective Metastatic Triple-Negative Breast Cancer Uncovers Therapeutic Vulnerabilities. https://app.cochat.ai/papers/10.1158/1535-7163.mct-12-0781
The paper
Craig, D. W., O'Shaughnessy, J. A., Kiefer, J. A., Aldrich, J., Sinari, S., Moses, T. M., Wong, S., Dinh, J., Christoforides, A., Blum, J. L., Aitelli, C. L., Osborne, C. R., Izatt, T., Kurdoglu, A., Baker, A., Koeman, J., Barbacioru, C., Sakarya, O., De La Vega, F. M., . . . Carpten, J. D. (2013). Genome and Transcriptome Sequencing in Prospective Metastatic Triple-Negative Breast Cancer Uncovers Therapeutic Vulnerabilities. Molecular Cancer Therapeutics. https://doi.org/10.1158/1535-7163.mct-12-0781

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.